ESMO 2018 | Pembrolizumab for frontline head and neck cancer: KEYNOTE-048 results

Barbara Burtness

The latest news in head and neck cancer was presented at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. Here, Barbara Burtness, MD, of Yale School of Medicine, New Haven, CT, presents the breaking news from the meeting. Prof. Burtness covers the Phase III KEYNOTE-048 trial (NCT02358031) of pembrolizumab for the frontline treatment of recurrent/metastatic head and neck squamous cell carcinoma.

Share this video